A recent study found that using spatial quantification of CD8 and PDL1 markers to quantify immune scoring is a novel in vitro diagnostic methods, which is capable to predict the efficacy of anti‐PD1/PDL1 immunotherapy in NSCLC, and is a potential powerful tool for evaluating the outcomes of cancer immunotherapy.265. The gene discussed is CD8A; the disease is non-small cell lung carcinoma.